RNS summary6 Jun 2025 08:13
NA therapeutics is a rapidly growing area of drug development with significant interest from large pharmaceutical companies and biotechs globally. The key challenge for all of these companies lies in delivering the drug safely and intact to the right tissues; this delivery challenge has not yet been solved. Nuvec® demonstrates all the key performance criteria to become the delivery platform of choice for the RNA therapeutics industry.
As the Company looks forward, we are therefore consolidating our efforts onto the Nuvec® platform. In the near term, our focus is to secure partnership agreements to monetise Nuvec® through licensing deals to get Nuvec® into third-party drug pipelines and, in the longer term, our strategy is to drive even greater value by developing our own pipeline of novel RNA therapeutics differentiated by the Nuvec® platform.
To deliver both of these opportunities, the Company needs to expand the commercial data pack supporting Nuvec®'s performance claims. This work has been made possible by the recent fundraise and is being executed over the coming 12-18 months with the support of the world-class operational leadership team that has been assembled.
The Company awaits the outcome of the FDA's consideration of our application for Orphan Drug Designation for ECP105 in order to finalise our decision-making on the strategy for this product.
Nuvec® has the potential to deliver a very significant increase in shareholder value, and on behalf of the Board, I would like to thank all of our shareholders for their continued patient support and look forward to providing further updates on our progress.
Sign In
Follow the stocks
